Biomedical subjects

P F De Vries Robbé

Publications and source records attributed to P F De Vries Robbé.

3 recordsLinked to original sources

PubMed2001

Efficient diagnostic test sequence: applications of the probability-modifying plot.

Excessive diagnostic testing rarely leads to complete certainty of the disease status of a patient. Because of constraints of health care budgets, physicians should be aware of the diminishing marginal gain of each subsequent test in a testing strategy related to costs. We developed the probability-modifying plot to determine economically efficient sequence of testing without losing clinical effectiveness. Two applications of the model are presented: diagnosis of Helicobacter pylori and diagnosis of benign prostatic hyperplasia. The probability-modifying plots are drawn to visualize and calculate the economic efficiency of all possible test sequences, meaning that although the different test sequences are equally accurate, some have even lower costs than others.

Decision Support Techniques↗

PubMed2000

Clinical problem analysis (CPA): a systematic approach to teaching complex medical problem solving.

The authors describe and discuss clinical problem analysis (CPA), an approach to solving complex clinical problems. They outline the five steps of the CPA model and the essential elements of each step. Next, they discuss the value of CPA's content-independent (methodical) approach and argue that teaching students to use CPA will enable them to avoid some common diagnostic reasoning errors and pitfalls. Finally, they compare CPA with two existing approaches to clinical problem solving.

Education, Medical, Undergraduate↗

PubMed1997

Two strategies for managing invasive aspergillosis: a decision analysis.

We devised a diagnostic approach based on screening plasma for an Aspergillus antigen with use of a sandwich enzyme-linked immunosorbent assay (ELISA), thoracic computed tomographic scanning, and radionuclide imaging for managing patients at risk for invasive aspergillosis. We used a decision analytic model to compare this alternative strategy with the conventional strategy, which relies only on the presence of clinical symptoms, persistent fever, and chest roentgenographic findings. Use of the alternative strategy reduced the number of patients who would receive antifungal treatment empirically, but this strategy was more expensive. The specificity of the sandwich ELISA had a significant impact on cost, but the sensitivity did not. A 13% prevalence of infection resulted in equal costs for both strategies. As much as 43.3% of the patients treated empirically could be given liposomal amphotericin B (L-AmB) before the conventional strategy became the most expensive. The costs of the alternative strategy were less than those of the conventional strategy when >5.3% of all patients, irrespective of strategy, were treated with L-AmB.

Amphotericin B↗